Novo Nordisk A/S (NVO)
46.94
+0.20
(+0.44%)
USD |
NYSE |
Aug 24, 16:00
47.05
+0.10
(+0.22%)
After-Hours: 20:00
Novo Nordisk EPS Diluted (Quarterly) : 0.7362 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.7362 |
| March 31, 2026 | 1.709 |
| December 31, 2025 | 0.9419 |
| September 30, 2025 | 0.7044 |
| June 30, 2025 | 0.9054 |
| March 31, 2025 | 0.9212 |
| December 31, 2024 | 0.9061 |
| September 30, 2024 | 0.9012 |
| June 30, 2024 | 0.648 |
| March 31, 2024 | 0.8273 |
| December 31, 2023 | 0.7073 |
| September 30, 2023 | 0.7309 |
| June 30, 2023 | 0.6304 |
| March 31, 2023 | 0.6329 |
| December 31, 2022 | 0.4121 |
| September 30, 2022 | 0.4297 |
| June 30, 2022 | 0.4185 |
| March 31, 2022 | 0.4692 |
| December 31, 2021 | 0.3654 |
| September 30, 2021 | 0.4181 |
| June 30, 2021 | 0.4261 |
| March 31, 2021 | 0.4414 |
| December 31, 2020 | 0.321 |
| September 30, 2020 | 0.3462 |
| June 30, 2020 | 0.3345 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.3725 |
| December 31, 2019 | 0.2733 |
| September 30, 2019 | 0.32 |
| June 30, 2019 | 0.3029 |
| March 31, 2019 | 0.3318 |
| December 31, 2018 | 0.27 |
| September 30, 2018 | 0.2914 |
| June 30, 2018 | 0.3401 |
| March 31, 2018 | 0.3631 |
| December 31, 2017 | 0.2658 |
| September 30, 2017 | 0.3127 |
| June 30, 2017 | 0.2969 |
| March 31, 2017 | 0.291 |
| December 31, 2016 | 0.2506 |
| September 30, 2016 | 0.2902 |
| June 30, 2016 | 0.2975 |
| March 31, 2016 | 0.2741 |
| December 31, 2015 | 0.2369 |
| September 30, 2015 | 0.2428 |
| June 30, 2015 | 0.2394 |
| March 31, 2015 | 0.286 |
| December 31, 2014 | 0.2098 |
| September 30, 2014 | 0.2205 |
| June 30, 2014 | 0.2435 |
| March 31, 2014 | 0.2231 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AstraZeneca PLC | 0.9849 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
| Merck & Co., Inc. | -0.5405 |
| Novartis AG | 1.706 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.265B |
| Revenue (Quarterly) | 12.21B |
| Total Expenses (Quarterly) | 8.946B |
| Enterprise Value | 170.94B |
| Gross Profit Margin (Quarterly) | 78.21% |
| Profit Margin (Quarterly) | 26.74% |
| Earnings Yield | 8.72% |
| Operating Earnings Yield | 11.19% |
| Normalized Earnings Yield | 9.068 |